Recent findings from the ACHIEVE-1 trial suggest that orforglipron, a novel oral GLP-1 receptor agonist, can provide significant glycemic control and weight loss in adults with early type 2 diabetes who have not yet received medication. This randomized, phase 3 trial involved 559 participants and lasted 40 weeks, revealing that each dose of orforglipron significantly reduced HbA1c levels and led to weight loss compared to placebo. Gastrointestinal adverse events were reported but mostly mild. This study could pave the way for oral diabetes management options.

Source: The New England Journal of Medicine